FDA Medical Device Advisory Committees: Panel Referral & Prep (2026)

Executive Summary

For sponsors navigating high-risk medical device approvals in the United States, referral to an FDA advisory committee represents one of the most critical and high-stakes milestones in the regulatory lifecycle. Convened under the Federal Advisory Committee Act (FACA), the FDA’s Medical Devices Advisory Committee (MDAC) brings outside clinical, scientific, and statistical experts together in a public forum to evaluate premarket applications, classification decisions, and complex safety issues.

However, regulatory teams frequently operate under misconceptions regarding when a panel meeting is required, how the panels are structured, and how advisory programs differ from formal committee meetings. Key realities of the advisory committee framework include:

• Statutory Referral Triggers: Under Section 515(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA generally refers first-of-a-kind Premarket Approval (PMA) applications to an advisory panel. Once the safety and effectiveness profile for a device type is well established, routine panel referral is discontinued at agency discretion.
• The 18 MDAC Panels: The Medical Devices Advisory Committee consists of 17 specialty panels (such as Circulatory System, Orthopaedic and Rehabilitation, and Radiology) plus the Medical Devices Dispute Resolution Panel, with a charter authorizing up to 159 standing members (122 voting and 37 non-voting representatives).
• Non-Binding Authority: Panel votes on safety, effectiveness, and risk-benefit balance are advisory. Peer-reviewed analyses of FDA advisory committee votes place FDA's alignment with panel recommendations at roughly 85% to 90% of votes, though the agency retains ultimate statutory authority to approve or deny an application regardless of the vote.
• Crucial Policy Distinctions: The Total Product Life Cycle Advisory Program (TAP) under MDUFA V is a voluntary sponsor-coaching pilot, not a FACA advisory committee. Conversely, Section 3302 of the Food and Drug Omnibus Reform Act of 2022 (FDORA) mandates annual MDAC panel meetings specifically for pandemic-preparedness devices through FY 2027.
• 2025–2026 Activity Shift: Across all FDA centers, total advisory committee meetings dropped sharply from 38 in 2024 to approximately 9 through August 2025, reflecting streamlined internal review practices while CDRH simultaneously expanded the TAP coaching program across all health-technology offices as of July 1, 2026.

---

Scenario & Direct Answer

Sponsor Question: Our company is submitting a first-of-a-kind Class III PMA for a novel cardiovascular implant. Will the FDA refer our application to an advisory committee panel, how will it affect our review timeline, and what is the strategic playbook to prepare for the meeting?

Direct Answer: Under Section 515(c) of the FD&C Act, the FDA is required to refer a PMA to an advisory panel if the application is for a first-of-a-kind device type or if the submission presents novel clinical, technological, or ethical questions. Once the FDA has established a clear review standard for that device category, routine panel referral is discontinued.

An advisory committee referral pauses the 180-day PMA review clock and typically adds 90 to 180 calendar days to the overall approval timeline due to public notice requirements, briefing document preparation, and meeting logistics. Although panel recommendations and votes on safety, effectiveness, and risk-benefit balance are technically non-binding, the FDA aligns with panel recommendations in the vast majority of decisions. Winning a panel vote requires an integrated preparation strategy centered on a bulletproof public Briefing Document, rigorous mock panels, and precise alignment with FDA’s clinical endpoint questions.

---

Structure of the FDA Medical Devices Advisory Committee (MDAC)

The Medical Devices Advisory Committee (MDAC) operates as an umbrella committee established under the Federal Advisory Committee Act (FACA) of 1972 (5 U.S.C. App. 2). Governed by its formal FDA charter, the MDAC provides independent expert advice to the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER).

The 18 Panels of the MDAC

The MDAC is chartered to operate with up to 159 standing members divided across 18 distinct panels. Each specialty panel reflects a specific medical discipline or administrative function:

Panel Name	Primary Clinical / Technical Focus	Key Device Types Evaluated
Anesthesiology and Respiratory Therapy	Airway management, mechanical ventilation, anesthesia delivery, pulse oximetry	Critical care ventilators, automated anesthesia delivery systems
Circulatory System	Structural heart, electrophysiology, vascular intervention, heart failure	Transcatheter valves, pacemakers, ventricular assist devices (VADs)
Clinical Chemistry and Clinical Toxicology	In vitro diagnostic assays, automated analyzers, toxicological screening	Continuous glucose monitors (CGMs), drug-testing IVDs, biomarker panels
Dental	Restorative dentistry, endodontics, periodontics, maxillofacial implants	Dental implants, bone grafting materials, orthodontic software
Ear, Nose, and Throat	Otology, audiometry, rhinology, laryngology	Cochlear implants, bone-anchored hearing aids, sinus implants
Gastroenterology and Urology	Endoscopy, bariatric devices, dialysis, urinary prostheses	Intragastric balloons, artificial urinary sphincters, hemodialysis machines
General and Plastic Surgery	Wound healing, surgical tools, aesthetic implants, tissue adhesives	Breast implants, surgical robotics, dermal fillers, wound dressings
General Hospital and Personal Use	Infusion pumps, hospital beds, disinfection equipment, personal protective gear	Smart infusion pumps, hemodialysis accessories, sterilizers
Hematology and Pathology	Coagulation assays, digital pathology, blood banking equipment	Whole slide imaging AI, automated cell counters, coagulation monitors
Immunology	Autoimmune IVDs, allergy testing, immunodiagnostic platforms	Multiplex immunoassays, transplant rejection diagnostic panels
Molecular and Clinical Genetics	Next-generation sequencing (NGS), companion diagnostics, gene panels	Oncology companion diagnostics, liquid biopsy assays, hereditary risk panels
Neurological	Neurostimulation, brain-computer interfaces (BCIs), neurovascular	DBS systems, stroke thrombectomy devices, intracranial stents
Obstetrics and Gynecology	Fetal monitoring, assisted reproduction, gynecologic surgery	Laparoscopic power morcellators, pelvic mesh, intrauterine devices
Ophthalmic	Cataract surgery, refractive surgery, retinal prostheses	Intraocular lenses (IOLs), excimer lasers, retinal implants
Orthopaedic and Rehabilitation	Joint reconstruction, spinal instrumentation, orthotics, prosthetics	Total hip/knee replacements, spinal fusion cages, powered exoskeletons
Radiology	Diagnostic imaging (CT, MRI, X-ray), radiotherapy, imaging AI	Proton therapy systems, mammography CAD/AI, MRI scanners
Microbiology Devices	In vitro diagnostic devices for clinical microbiology, virology, and infectious disease	Microbial identification systems, blood culture instruments, molecular infectious disease assays
Medical Devices Dispute Resolution	Administrative and scientific disputes under Section 562 of FD&C Act	Appealed PMA/510(k) denials, NSE determinations, reclassification disputes

[!NOTE] Charter Membership Composition: The MDAC charter establishes a maximum of 159 standing members, comprising 122 voting members (physicians, biostatisticians, bioethicists, and engineers) and 37 non-voting members (18 consumer representatives and 19 industry representatives). For specific panel meetings, the FDA frequently supplements standing members with temporary voting members possessing specialized expertise relevant to the target submission.

---

Recommended Reading

FDA Pediatric Medical Device Regulation: Pathways, Section 515A, and Waivers

Regulatory Clinical Evidence2026-07-26 · 18 min read

When Is an Advisory Committee Panel Meeting Required vs. Discretionary?

Advisory panel referrals occur under specific statutory mandates, administrative provisions, or agency initiatives. Understanding the precise legal triggers allows regulatory teams to project panel risk early in development.

Decision Pathway for Advisory Panel Referral

1. PMA / Reclassification Submission Filed
   • Is it a first-of-a-kind device type or novel technological mechanism under Section 515(c)?
     • Yes: Section 515(c) referral is expected. The PMA review clock is paused, and a public Federal Register notice is issued at least 15 days prior to the meeting.
     • No: Proceed to internal CDRH review unless major safety/effectiveness concerns exist.
2. Discretionary Referral Evaluation
   • Does the submission introduce complex safety signals, controversial surrogate endpoints, or postmarket adverse event trends?
     • Yes: CDRH division director exercises administrative discretion to convene an MDAC panel meeting.
     • No: Standard internal FDA review continues without a panel meeting.

1. Premarket Approval (PMA) Applications — Section 515(c)

Under Section 515(c) of the FD&C Act (21 U.S.C. § 360e(c)), as implemented at 21 CFR 814.44, the FDA is statutorily instructed to refer a PMA application to an advisory committee for review and recommendation if:

1. The PMA is for a first-of-a-kind device (a novel Class III device for which no predicate or previous PMA approval exists); or
2. The application raises novel scientific, clinical, or technological questions that lack established regulatory precedents; or
3. The FDA determines that expert panel consultation is necessary to evaluate the risk-benefit profile.

Once the FDA has approved several devices within a specific product code and the clinical safety and effectiveness endpoints are well understood, the agency systematically discontinues routine panel referral for subsequent PMAs in that category.

2. Device Reclassification — Section 513(e) & 513(f)

Under Section 513(e) of the FD&C Act, as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, reclassification of a device type (e.g., downclassifying a Class III device to Class II, or upclassifying a Class II device to Class III) is conducted via administrative order rather than formal rulemaking.

Before issuing a final reclassification order, the FDA may consult an advisory committee panel. For example, during the reclassification of bone growth stimulators or surgical mesh products, panel meetings were convened to review real-world evidence and postmarket adverse event data.

3. De Novo Classification & 510(k) Submissions

• De Novo Classification: While De Novo requests are designed for novel low-to-moderate risk devices, panel referrals are rare. However, if a De Novo request introduces unprecedented clinical risks or controversial surrogate endpoints, CDRH may exercise its discretion to convene a panel.
• 510(k) Premarket Notifications: Panel referrals for 510(k) clearance are exceptionally uncommon. When a 510(k) is referred to a panel, it almost always involves complex sub-population safety issues or novel diagnostic claims (such as high-risk IVDs). More frequently, panel discussions arise when CDRH considers creating a new special control or reclassifying a 510(k) product type.

4. Postmarket Safety & Public Health Emergencies

The FDA also convenes advisory committees outside the premarket approval context to address emergent postmarket safety signals, such as:

• Long-term safety concerns regarding breast implants (General and Plastic Surgery Panel);
• Metal-on-metal hip implant failures (Orthopaedic Panel);
• Cybersecurity vulnerabilities in connected medical systems (Digital Health / General Hospital Panel).

---

Sponsor Preparation Playbook: Executing a Successful Panel Strategy

An advisory committee meeting is a public, highly rehearsed, and rigorous event. Sponsors typically receive formal notification of a panel meeting 3 to 6 months in advance. Managing this process requires flawless execution across five core workstreams.

Step 1: Mastering the Timeline & Federal Register Notice

Under FACA rules and FDA regulations (21 CFR Part 14), the FDA must publish a notice in the Federal Register at least 15 calendar days prior to the meeting date, though notice is typically published 30 to 60 days in advance.

T-180 Days: FDA confirms panel referral; sponsor establishes Panel Task Force
T-120 Days: Sponsor submits draft Briefing Document to FDA for alignment
T-60 Days:  Conduct Mock Panel 1 (Unkind Mock with external experts)
T-30 Days:  Final Briefing Document filed; Conduct Mock Panel 2 (Finetuning)
T-2 Days:   FDA posts Sponsor and FDA Briefing Documents on public website
T-0 Day:    Advisory Committee Meeting (Public Presentations & Voting)

Step 2: Constructing the Sponsor Briefing Document

The Briefing Document (often 50 to 100 pages plus appendices) is the single most critical written submission. It must present a compelling, data-driven narrative of safety and effectiveness without appearing evasive.

• Executive Summary: Must state the exact indication for use, pivotal trial results, primary endpoints, and the proposed risk management plan within the first 5 pages.
• Trial Design & Endpoints: Detail primary efficacy and safety endpoints, statistical hypothesis testing, drop-out rates, missing data imputations, and protocol amendments.
• Subgroup & Sensitivity Analyses: Proactively address subgroup variances (age, sex, ethnicity, disease severity) and present sensitivity analyses for protocol deviations.
• Risk Mitigation & Postmarket Plan: Proactively present proposed Post-Approval Studies (PAS) or Risk Evaluation and Mitigation Strategies (REMS)-equivalent controls.

[!IMPORTANT] Public Disclosure: Exactly two business days before the meeting, the FDA posts both the Sponsor Briefing Document and the FDA Briefing Document online. Sponsors must meticulously audit their briefing materials for trade secrets and confidential commercial information (CCI) prior to submission so redactions are finalized well ahead of public posting.

Step 3: Anticipating the FDA Briefing Document & Questions

The FDA Briefing Document contains the agency's independent assessment of the sponsor's data, often highlighting statistical vulnerabilities, adverse event signals, or missing data.

• Analyzing FDA Draft Voting Questions: FDA provides draft voting and discussion questions to the panel and sponsor shortly before public posting. Questions typically follow a standard tripartite structure:
  1. Discussion Question: Does the panel agree that the clinical data demonstrate an acceptable safety profile?
  2. Voting Question 1 (Safety): Is there reasonable assurance that the device is safe for its intended use?
  3. Voting Question 2 (Effectiveness): Is there reasonable assurance that the device is effective for its intended use?
  4. Voting Question 3 (Risk-Benefit): Do the benefits of the device outweigh the risks for the proposed indication for use?

Step 4: Rehearsing via Mock Panels

Successful sponsors conduct at least two full-scale "Mock Panels" using independent former FDA officials, clinicians, biostatisticians, and patient advocates who simulate panel members.

• The "Unkind" Mock: Held at T-60 days, this mock forces executive presenters to answer harsh, unscripted Q&A scenarios without relying on scripted slides.
• Slide Repository Management: Sponsors prepare a core 20-to-30-minute presentation plus a structured backup repository of 300 to 500 hyper-indexed Q&A slides accessible within seconds during the panel Q&A session.

Step 5: Voting Mechanics and Post-Meeting Actions

Advisory committee votes are conducted publicly. Each voting member casts an individual vote on Safety, Effectiveness, and Risk-Benefit, followed by a brief verbal rationale.

• Positive Vote Outcome (Majority YES on Risk-Benefit):
  • FDA resumes the PMA clock.
  • Final approval is typically issued within 90 to 120 days, usually conditioned on Post-Approval Study (PAS) commitments.
• Negative Vote Outcome (Majority NO on Risk-Benefit):
  • FDA issues a Major Deficiency Letter or Approvable with Conditions Letter requiring additional clinical trials or a significantly narrowed indication.
  • Approvals following a negative vote are extremely rare.

---

TAP Program vs. MDAC Panels vs. FDORA Section 3302

Considerable confusion exists in industry literature regarding the relationship between FDA advisory committees and newer administrative advisory initiatives. Clarifying these boundaries is vital for accurate regulatory planning.

Dimension	MDAC Advisory Committee Panels	Total Product Life Cycle Advisory Program (TAP)	FDORA Section 3302 Pandemic Panels
Legal Basis	Federal Advisory Committee Act (FACA, 5 U.S.C. App. 2)	MDUFA V Commitment (Voluntary Administrative Pilot)	FDORA § 3302 / FD&C Act Mandate (Public Law 117-328)
Public Status	Public hearing, open Q&A, public voting record	Confidential sponsor coaching, closed strategic meetings	Public hearing, open Q&A, public voting record
Primary Purpose	Formal premarket approval & reclassification advice	Early, iterative multi-stakeholder coaching (CDRH, payers, clinicians)	Annual public panel on pandemic & countermeasure devices
Enrolled Volume	~5 to 15 device panel meetings per year	133+ enrolled devices across all OHTs (as of July 1, 2026)	At least 1 meeting annually through Sept 30, 2027
Formal Output	Non-binding voting recommendation to CDRH Director	Informal strategic feedback, early trial design alignment	Policy recommendations for pandemic device assessment

The Total Product Life Cycle Advisory Program (TAP)

Launched on October 12, 2022 under the Medical Device User Fee Amendments of 2022 (MDUFA V), the Total Product Life Cycle Advisory Program (TAP) Pilot is a voluntary coaching and engagement program for breakthrough and high-priority novel devices.

• Key Difference: TAP is not an advisory committee under FACA. TAP does not involve formal public hearings, public voting, or Federal Register notices.
• Function: TAP provides enrolled sponsors with frequent, informal strategic interaction with CDRH advisors, clinical experts, professional societies, and payers early in the development lifecycle.
• Expansion Milestone: As of July 1, 2026, CDRH expanded the TAP program to encompass all health-technology offices (OHTs), with over 133 novel devices enrolled.

FDORA Section 3302 Statutory Requirement

Section 3302 of the Food and Drug Omnibus Reform Act of 2022 (FDORA), enacted under Public Law 117-328, introduced a specific statutory mandate directing the Secretary to convene one or more advisory committee meetings under the MDAC:

• Mandate: Requires the FDA to hold an MDAC panel meeting at least annually through September 30, 2027.
• Scope: Focused specifically on medical devices intended for use in public health emergencies, pandemic preparedness, and countermeasure readiness.
• Purpose: To evaluate technical standards, premarket assessment criteria, and real-world performance protocols for critical diagnostic, protective, and therapeutic devices.

---

Recommended Reading

Medicare OPPS Device Pass-Through: CY2026 Categories and Criteria

Reimbursement & Market Access Regulatory2026-07-26 · 20 min read

2025–2026 Advisory Committee Trends & Historical Panel Case Studies

Recent regulatory activity reveals a shifting paradigm in how the FDA utilizes public advisory panels relative to internal review processes.

Annual Advisory Committee Meeting Activity (All FDA Centers)

• 2024 (Full Year): 38 total public advisory committee meetings across CDER, CBER, and CDRH (per a 2025 trade-press tally).
• 2025 (Through August): 9 total public advisory committee meetings across all centers — a steep drop that, annualized, implies roughly a two-thirds decline from the 2024 pace.

Detailed Panel Case Studies

To understand how panel dynamics play out in practice, consider three representative case studies (illustrative composites drawn from recurring device-panel issues):

Case Study 1: Neurological Devices Panel — Brain-Computer Interfaces (BCIs)

• Context: Evaluating early feasibility and pivotal trial endpoints for fully implanted neural recording arrays.
• Panel Focus: Risk of long-term intracranial lead degradation, infection monitoring, and clinical utility of motor-function restoration.
• Key Outcome: Panel supported the risk-benefit profile for severely paralyzed patients and recommended standardized explant protocols with long-term post-approval follow-up. (Illustrative composite based on recurring panel issues for novel implantable neurotechnology.)

Case Study 2: Circulatory System Panel — Transcatheter Tricuspid Valve Repair

• Context: PMA evaluation of a first-of-a-kind transcatheter repair system for severe tricuspid regurgitation.
• Panel Focus: Balancing quality-of-life improvements against primary mortality and heart failure hospitalization endpoints.
• Key Outcome: A favorable panel vote on safety and effectiveness led to CDRH PMA approval conditioned on a post-approval registry. (Illustrative composite reflecting the typical outcome pattern for novel structural-heart devices.)

Case Study 3: General and Plastic Surgery Panel — Surgical Mesh Postmarket Safety

• Context: Postmarket safety review of long-term adverse events associated with surgical mesh.
• Panel Focus: Adequacy of physician labeling, patient selection criteria, and real-world data collection.
• Key Outcome: FDA subsequently strengthened labeling, reclassified certain transvaginal mesh products to Class III, and updated special controls. (Illustrative composite of the multi-year postmarket actions on surgical mesh.)

---

Strategic Recommendations for Regulatory Leaders

When evaluating advisory committee risk for Class III devices or novel technologies:

1. Conduct an Early Panel Audit at the Pre-Sub Stage: During your initial Q-Sub meeting, request explicit CDRH feedback on whether the proposed indication or endpoint novelties will trigger Section 515(c) panel referral.
2. Leverage the TAP Program If Eligible: Enrolling in TAP provides direct advisory feedback without public panel exposure, allowing teams to align on clinical trials before data collection begins. For details on breakthrough criteria, see our guide on FDA Breakthrough Device Designation.
3. Model Panel Delays in the Commercialization Budget: Incorporate a 6-month buffer into your financial model for PMA approvals if panel referral is likely. Review the baseline review framework in our PMA vs. 510(k) Comparison Guide.
4. Treat the FDA Briefing Document as the True Test: Focus mock panel preparation on addressing potential FDA critiques rather than polishing the sponsor's presentation.

---

Frequently Asked Questions (FAQs)

Is an advisory committee meeting required for every PMA submission?

No. Section 515(c) requires panel referral primarily for first-of-a-kind PMA devices or submissions raising novel scientific questions. Once a device type has established safety and effectiveness precedents, subsequent PMAs in that product code are evaluated directly by CDRH review staff without a panel meeting.

Can the FDA approve a device after the advisory committee votes "No" on Risk-Benefit?

Yes. Advisory committee recommendations are non-binding. The FDA retains final legal authority to approve or deny a PMA. However, approving a device after a negative panel vote is extremely rare and typically occurs only if the sponsor agrees to strict post-approval study (PAS) commitments or significantly narrows the indication for use.

How much advance notice does the FDA give a sponsor before a device panel meeting?

While FACA requires a minimum of 15 calendar days notice in the Federal Register, CDRH typically coordinates panel meeting dates with the sponsor 3 to 6 months in advance to allow adequate time for Briefing Document submission, logistical arrangements, and public posting.

How does De Novo classification interact with advisory panels?

De Novo requests are evaluated under Section 513(f)(2) for low-to-moderate risk novel devices. While CDRH has authority to refer a De Novo request to an advisory committee, panel referrals for De Novo devices are rare. Learn more in our FDA De Novo Classification Guide.

---

Recommended Reading

FDA Safer Technologies Program (STeP) for Medical Devices: Complete Regulatory Guide

Regulatory 510(k)2026-07-24 · 20 min read

Related Guides & Resources

• PMA vs. 510(k) Comparison: Regulatory Pathways & Decision Frameworks
• FDA De Novo Classification Pathway Guide
• FDA Breakthrough Device Designation: Requirements & TAP Enrollment
• FDA 510(k) Clearances by Medical Specialty Advisory Committee Analysis
• FDA Bone Growth Stimulator Reclassification Guide